BRIDGEWATER, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced the closing today of its previously announced public offering of its 1.75% convertible senior notes due 2025. Insmed issued and sold in the public offering $450 million aggregate principal amount of its 1.75% convertible senior notes due 2025, including $50 million aggregate principal amount of the notes pursuant to the exercise on January 24, 2018 of the underwriters’ option to purchase additional notes, solely to cover over-allotments. The net proceeds to Insmed from the offering were approximately $435.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Insmed.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The Company's lead product candidate is ALIS for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

